report of the thirty fifth session of the joint ... · 12.2 selection of two members of the jcb...

© World Health Organization on behalf of the Special Programme for Research and Training in Tropical Diseases,

2012. All rights reserved. This health information product is intended for a restricted audience only. It may not be

reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means.

DISTRIBUTION: RESTRICTED

TDR/JCB(35)/12.3

ORIGINAL: ENGLISH

REPORT OF THE THIRTY‐FIFTH SESSION OF THE JOINT COORDINATING BOARD (JCB)

WHO Headquarters, Geneva, Switzerland

18‐20 June 2012

TDR/JCB(35)/12.3 .

TABLE OF CONTENTS

Page

I Introduction ................................................................................................................................3

II Summary of proceedings ............................................................................................................3

1. Statutory business ................................................................................................................................ 3

1.1 Election of the Chair and Vice Chair ................................................................................................ 3

1.2 Approval of the Report of JCB(34) .................................................................................................. 4

1.3 Adoption of the Agenda ................................................................................................................. 4

2. Report by the Chair of the Joint Coordinating Board ........................................................................ 4

3. Report of the Standing Committee ...................................................................................................... 5

4. Report by the Chair of the Scientific and Technical Advisory Committee (STAC)........................... 6

5. Programme Review .............................................................................................................................. 6

5.1 Follow‐up to the JCB(34) decisions and recommendations ............................................................ 6

5.2 Interim External Review ................................................................................................................. 6

5.3 Operational and financial performance .......................................................................................... 6

6. Programme Budget 2012-2013 and future strategic direction ........................................................... 7

6.1 Future strategic direction and reorganization ................................................................................ 7

6.2 Workplan and Programme Budget for the biennium 2012‐2013 and outlook for the biennium 2014‐2015 ...................................................................................................................... 8

7. Summary of recommendations and decisions of day 1 ...................................................................... 9

8. Review of TDR governance ................................................................................................................. 9

9. Resource Mobilization and Communications Strategy .................................................................... 10

10. Technical presentation ...................................................................................................................... 11

11. Global Report for Infectious Diseases of Poverty ............................................................................. 11

12. Selection of JCB members ................................................................................................................ 12

12.1 Results of the election of four members under Paragraph 2.2.1 of the TDR Memorandum of Understanding .................................................................................................. 12

12.2 Selection of two members of the JCB according to Paragraph 2.2.3 of the TDR Memorandum of Understanding .................................................................................................. 12

13. Membership of the Scientific and Technical Advisory Committee (STAC) .................................... 12

14. Review of TDR key achievements since JCB(34) and outlook 2012-2013 ...................................... 13

15. Summary of decisions and recommendations .................................................................................. 13

16. Closing session ................................................................................................................................... 13

Report of the 35th Session of the JCB

.

I Introduction

The Thirty‐fifth Session of the Joint Coordinating Board (JCB) of the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) took place at WHO headquarters in Geneva from 18 to 20 June 2012. The session was chaired by Dr Sue Kinn from the United Kingdom and attended by all JCB members except Brazil, Côte d’Ivoire, Portugal and the United Arab Emirates who sent their apologies. Representatives of several governments and organizations also attended the session as observers (see Annex 2).

The deliberations of JCB(35) focused on TDR’s new strategy 2012‐2017, TDR’s achievements since JCB(34) and the Programme Budget and work plan for the Biennium 2012‐2013. Important decisions taken included the adoption of TDR’s new strategy and measures to further strengthen TDR governance.

II Summaryofproceedings Openingsession Key messages

In her opening remarks, Dr Sue Kinn, welcomed the JCB members and observers. She extended a warm welcome to Dr John Reeder, the new Director of TDR. She also extended a special welcome to the Drugs for Neglected Diseases initiative (DNDi) which joined the JCB in January 2012 as the first nongovernmental member since the Rockefeller Foundation’s membership on the JCB ended in 1981, and to Dr Mario Henry Rodriguez‐Lopez, Chair of the TDR Scientific and Technical Advisory Committee (STAC), who played an important role in TDR’s strategic re‐orientation.

Dr Hiroki Nakatani, WHO Assistant Director‐General for HIV/AIDS, TB, Malaria and Neglected Tropical Diseases, welcomed the delegates on behalf of WHO and conveyed special greetings from Dr Margaret Chan, Director‐General of WHO. Dr Nakatani paid tribute to TDR’s rich history of achievements, which includes development of tools and strategies that lie at the heart of efforts to eliminate diseases such as leprosy, Chagas' disease, lymphatic filariasis and onchocerciasis (African river blindness) and the provision of evidence for policies and approaches now used to control a number of infectious diseases, including malaria, dengue and visceral leishmaniasis. He underlined the importance of this Board meeting, which comes at a time when TDR looks forward to guidance and support from the JCB in moving forward.

Dr John Reeder, Director TDR, conveyed his commitment and motivation to lead TDR through a challenging period, expressing confidence that TDR is emerging reinvigorated, and thanking the JCB for its continued support and guidance.

1. Statutory business

1.1 ElectionoftheChairandViceChair

The Chair JCB expressed her appreciation and thanks for the support she received from the Vice‐Chair JCB, Dr Modest Mulenga from Zambia. Dr Kinn also extended her thanks to the outgoing Rapporteur, Dr Maria‐Teresa Bejarano from Sweden, for her support and excellent work.

TDR/JCB(35)/12.3 .

1.2 ApprovaloftheReportofJCB(34)

The Report of JCB(34) was circulated to the members of the JCB in July 2011.

1.3 AdoptionoftheAgenda

The Draft Agenda of JCB(35) was circulated to the JCB members and observers in March 2012 and the Draft Annotated Agenda was made available on the JCB SharePoint site a month before the meeting.

2. Report by the Chair of the Joint Coordinating Board

Key messages

The Chair JCB briefly recalled some of the main recommendations made by JCB(34) and commended TDR for the follow‐up action taken.

A key highlight happened the day after JCB(34) closed when TDR was awarded the 2011 Gates Award for Global Health at a ceremony in Washington DC. This is a great achievement and recognition of TDR's work over its 35 year history.

In July 2011, Chair JCB wrote a letter to the TDR co‐sponsors and launched an appeal with TDR’s donors for additional funding. Three key donors of TDR – Japan, Sweden and the United Kingdom ‐‐ provided TDR with special additional financial resources.

At the end of August 2011, Dr Robert Ridley left TDR to become the Pro Vice Chancellor of the University of Malawi. Dr Marie‐Paule Kieny, WHO Assistant Director‐General for Innovation, Information, Evidence and Research and TDR Special Programme Coordinator, took up the position of ad‐interim Director of TDR until the new Director, Dr John Reeder, took office in February 2012.

Decisions

Dr Modest Mulenga from Zambia was elected as Vice‐Chair JCB for a second term of one year.

Dr Ignace Ronse from Belgium was elected as Rapporteur for JCB(35).

Decisions

The JCB(34) report was approved.

Future JCB reports will be sent to JCB representatives for electronic approval within two weeks of the meeting. There will be no need to table the report again for approval at the next JCB.

Decision

The Agenda for JCB(35) was approved.


.

In November 2011, the Chair and Vice‐Chair JCB attended, ex officio, the meeting of the Standing Committee in Berlin. They also participated in the deliberations of the Standing Committee in Washington DC in February 2012. The Chair and Vice Chair also actively participated in a number of Standing Committee consultations by teleconference.

In December 2011, the JCB received and approved electronically, a revised Programme Budget for the Biennium 2012‐2013. This marked an important milestone in TDR’s reorganization process.

3. Report of the Standing Committee

Key messages

The TDR Standing Committee (SC) recommended that TDR should refocus its activities in two areas where the Programme has comparative advantages and is recognized to be a key global player: (i) implementation research in close partnership with disease control programmes; and (ii) capacity building in disease endemic countries for health research on infectious diseases of poverty.

The SC welcomed the presentation made in Washington by the new Director TDR shortly after taking office and endorsed the strategic directions that he outlined. The SC recommended including the following as key guiding principles during the strategy development process: value for money, quality, equity and innovation.

The SC discussed extensively the issue of TDR governance and recommended that action should be taken to enhance accountability and to clarify the role and function of the TDR governing bodies and, in particular, decision‐making processes.

The SC recommended that all TDR project proposals should be submitted on the basis of full cost recovery (TDR recently introduced this policy).

The SC recommended a TDR Programme Budget for the Biennium 2012‐2013 of US$ 60 million and a further reduction of staff to 30 from its current staff of 58.

Decision

The report of the Chair JCB was accepted.

Decision

The report of the Standing Committee was accepted.

TDR/JCB(35)/12.3 .

4. Report by the Chair of the Scientific and Technical Advisory Committee (STAC)

Key messages

The Chair of STAC, Professor Mario Henry Rodriguez‐Lopez, highlighted the role STAC played in the review of TDR’s portfolio of activities, the Programme Budget 2012‐2013 and the strategy setting process. As Chair of STAC, he participated in the deliberations of the Standing Committee and chaired a meeting of a sub‐group of the STAC that took place in November 2011, as well as the 2012 annual meeting of STAC which took place in April 2012.

STAC provided useful guidance in the elaboration of TDR’s new strategy and gave its endorsement to the strategic orientations. STAC also advised on the results‐based approach to priority setting and budget allocation.

Feedback was provided on how to best utilize TDR’s existing networks and on linking with WHO disease control programmes to strengthen collaboration in addressing priorities.

Note: A comprehensive STAC report was made available to the JCB.

5. Programme Review

5.1 Follow‐uptotheJCB(34)decisionsandrecommendations

Key messages

TDR has kept up‐to‐date a detailed table with actions taken in response to the decisions and recommendations from JCB(34). Examples from the table were presented.

A TDR risk management framework is under development, addressing risks associated with financial, portfolio and project management.

5.2 InterimExternalReview

Key message

The scope and quality of the analysis provided by the Interim External Review was welcomed by the JCB. The Review has been particularly useful for the future strategic orientations of TDR and for the review of TDR’s governance. Actions have been taken to address the key recommendations.

5.3 Operationalandfinancialperformance

Key messages

TDR has now put into place the recommendation to stop subsidizing designated funding (DF) projects using core funding (UD) and is currently renegotiating donor agreements to include full staff costs wherever possible.

Decision

The report of the STAC was accepted.


.

TDR presented the Results Report for the second year. The presentation was appreciated by the JCB and is regarded as a useful reporting tool.

Designated funding is deposited and managed in separate accounts.

TDR should differentiate clearly between designated and undesignated (core) funding for budget planning and reporting

Designated funding should be listed by project.

6. Programme Budget 2012‐2013 and future strategic direction

6.1 Futurestrategicdirectionandreorganization

Key messages

The presentation of the new strategy by Director TDR generated a lot of positive feedback. The JCB commended the focus on health impact and the cross‐sectoral approach.

The JCB welcomed the proposed new working model, which focuses more on facilitation and coordination than direct implementation by TDR staff. The JCB encouraged TDR to further step up its collaboration with countries, partners (including co‐sponsors) and networks.

There was a consensus that the JCB should not micro‐manage TDR’s re‐profiling process, which will follow WHO’s rules and regulations and should leave TDR with the required skillset to implement its new strategy. However, the JCB reaffirmed that the reorganization should be carried out within the approved budget framework (which foresees a TDR staff ceiling of 30 people).

Decision

The TDR 2011 Results Report was endorsed.

Recommendation

The Performance Assessment Framework needs to be updated, adjusting expected results and targets to the outcomes of the new strategy and workplan, ensuring measures for outcomes of publications, training courses and networks are included.

Decision

JCB approved TDR’s new strategy which focuses on intervention and implementation research, research capacity strengthening and knowledge management.

Recommendation

JCB advised that ethics networks, research management strengthening and advocacy for global and regional policies should be covered under research capacity strengthening and networks.

TDR/JCB(35)/12.3 .

6.2 WorkplanandProgrammeBudgetforthebiennium2012‐2013andoutlookforthebiennium2014‐2015

Key messages

At its meeting in October 2011, the Standing Committee reviewed various budget scenarios and recommended a budget ceiling of US$ 60 million based on a staff count of 30. In December 2011 this budget was approved, following electronic consultation by the JCB.

The JCB responded positively to the fact that for the first time the TDR budget is based entirely on expected results and each expected result is costed.

The JCB recognized the fact that STAC has looked not only at the technical aspects but has also provided guidance in allocating budgets for expected results.

Decisions

JCB authorizes TDR to accept designated funding beyond the current budget ceiling for 2012‐2013, providing that the following three criteria are met. The designated funding:

1. supports the achievement of outcomes included in the TDR strategy.

2. fully covers the cost of activities and staff, thereby requiring no cross‐subsidy from core resources (undesignated funds).

3. is monitored in separate accounts.

Any designated funding beyond the approved ceiling which does not meet the above criteria, for example because it requires co‐investment of core resources, shall only be accepted by TDR following consideration of the Standing Committee and a decision by the JCB.

JCB reconfirmed its approval of the 2012‐2013 biennium Programme Budget of US$ 60 million, originally approved in December 2011.

Recommendations

A conservative approach should continue to be used when forecasting income.

In the future TDR should develop budget scenarios in order to be able to adjust the budget, if necessary, to the actual income received. Future Programme Budgets should contain a clear differentiation for each budget line between designated and undesignated funding.

TDR co‐sponsors are encouraged to financially support joint activities with TDR (e.g. TDR/UNICEF implementation research).

TDR should give priority to supporting research activities that are part of disease endemic countries’ comprehensive national health plans.

The budget line for coordination should be deleted and integrated into the budget lines for output.


.

7. Summary of recommendations and decisions of day 1

The decisions and recommendations of day 1 were summarized and discussed at the beginning of day 2.

8. Review of TDR governance

Key discussion points

Following JCB(34) and the recommendations of the Interim External Review, a JCB Working Group on Governance was created to consider options for increasing the effectiveness of TDR governance.

Options were presented for

a. decreasing the membership of the JCB under paragraph 2.2.2 of the MOU;

b. prolonging the term of office of the Chair and Vice Chair JCB; and

c. creating a JCB sub group with delegated power of authority from the JCB to take decisions on matters requiring attention in between the annual sessions of the JCB, and to facilitate decision‐making by the JCB.

Two options were also presented for reforming the Standing Committee:

a. to discontinue the ex officio participation in the Standing Committee and focus its deliberations in particular on matters related to the co‐sponsorship of the Programme; and

b. to continue the current practice but enlarge the participation in the Standing Committee and make it more representative.

The JCB supported a reduction of membership of the JCB under paragraph 2.2.2 of the MOU, but pointed out that this should not affect the important role that developing countries play in the governance of TDR, but rather constitute a stimulus to form informal constituencies or apply for JCB membership as resource contributors.

There was broad agreement around the expectation that JCB members should more closely engage in the governance process by nominating representatives who could stay in contact with the secretariat throughout their term of membership, including in between the annual JCB sessions.

The proposal to extend the term of office of the Chair JCB from 2 to 3 years and for the Vice‐Chair JCB from 1 to 2 years was welcomed for ensuring continuity and strengthening the effectiveness of their important function and role.

Following a rich discussion, the JCB opted for strengthening the current practice in respect of the Standing Committee meetings, including by providing the Standing Committee with Standard Operating Procedures (SOPs).

The JCB decided not to create a JCB sub‐group, but agreed with the possibility to establish, on a temporary basis, task related ad hoc committees if and when required, to deliberate on particular issues and/or prepare for JCB decision‐making.

TDR/JCB(35)/12.3 .

9. Resource Mobilization and Communications Strategy

Key messages

The fundraising environment remains challenging, however there are potential new opportunities for TDR to mobilize resources with an increased focus on achieving the Millennium Development Goals, the focus on climate and environmental change, strengthening health systems and evidence‐based delivery of health programmes.

Programme efficiency and effectiveness are important for donor funding decisions. Donors pay more attention today to transaction costs, impact assessments, evaluations and reporting on results achieved. The TDR Performance Assessment Framework is a key tool in this regard and should demonstrate the value and comparative advantage of undesignated funding.

The JCB commended the continued strong commitment of key donors and encouraged all JCB members to find ways of supporting TDR in their countries and regions. Director TDR intends to promote TDR’s new strategy with existing and potential new donors.

Disease endemic countries are encouraged to duly acknowledge the research support provided by TDR and to recognize the importance of their partnership with TDR.

TDR’s recognized convening power and reputation for high quality research should be promoted as key comparative advantages of the Programme.

Decisions

JCB decided to reduce its membership under paragraph 2.2.2 of the Memorandum of Understanding (MoU) from twelve to six members (one per WHO region). Informal constituencies could be formed under paragraph 2.2.2 to allow further countries to be represented on the JCB, but funding support to participate in the JCB will be limited to one representative per region.

The term of office of the Chair of the JCB is extended from 2 to 3 years and the Vice‐Chair from 1 to 2 years.

The Standing Committee will systematically expand its deliberations beyond the four co‐sponsors of TDR to include ex‐officio participation of the Chair and the Vice‐Chair of the JCB, one representative of the JCB resource contributors group, one representative of the DEC group and the chair of STAC. The representatives of the resource contributors group and DECs will be nominated by the JCB.

The Standing Committee will develop its own standard operating procedures (SOPs), for review by WHO Legal Counsel and submission to the JCB for its approval. The SOPs should include the expanded ex officio participation in the Standing Committee’s deliberations.

The representative of Belgium was nominated as the representative of the JCB resource contributor group and the representative of Djibouti was nominated as the representative from the JCB DEC group in the expanded Standing Committee deliberations.

Recommendation

JCB recommended that members give clear terms of reference to their representatives in order to allow them to perform effectively on the JCB.


.

10. Technical presentation

Dr Sodiomon Sirima, Director of the National Malaria Research and Training Center in Burkina Faso gave a presentation on TDR‐led implementation research for better control of pneumonia and malaria at community level in Burkina Faso.

Key message

JCB members noted the collaborative approach between the centre, TDR and other stakeholders and emphasized the need to link such research projects to national health programmes in countries to foster long term sustainability.

11. Global Report for Infectious Diseases of Poverty

Professor David Molyneux from the Liverpool School of Tropical Medicine highlighted key issues from the Global Report, underlining the substantive body of knowledge reflected in the report which should find its way to practical application.

Key message

The JCB commended the scope of the report and TDR for its role in facilitating its publication, bringing together different sets of expertise. The report merits wide dissemination.

Recommendations

TDR core contributors should harmonize their reporting requirements and accept TDR’s reporting through the JCB.

Director TDR should engage in a high level dialogue with the Global Fund to Fight AIDS, Tuberculosis and Malaria to explore collaboration aimed at promoting evidence‐based sustainable interventions.

TDR should further strengthen its collaboration with WHO’s disease control programmes.

TDR/JCB(35)/12.3 .

12. Selection of JCB members

12.1 ResultsoftheelectionoffourmembersunderParagraph2.2.1oftheTDRMemorandumofUnderstanding

12.2 SelectionoftwomembersoftheJCBaccordingtoParagraph2.2.3oftheTDRMemorandumofUnderstanding

13. Membership of the Scientific and Technical Advisory Committee (STAC)

Key discussion points

JCB discussed the options proposed by the JCB Working Group on Governance, considering also the input received from Chair STAC. A smaller STAC was considered to enhance its effectiveness and to be in line with the reduction of TDR staff.

JCB recognized, however, that STAC may require co‐opting external experts and recommended this to be done within the approved budget.

Elections

JCB re‐elected for membership from 1 January 2013 until 31 December 2016 the constituencies of:

(1) Germany and Luxembourg

(2) Panama and Spain

(3) United Kingdom of Great Britain and Northern Ireland and the United States

JCB elected as a new member from 1 January 2013 until 31 December 2016:

(4) Turkey

Elections

JCB re‐elected for membership from 1 January 2013 until 31 December 2016:

(1) Zambia

JCB elected as a new member from 1 January 2013 until 31 December 2016:

(2) Burkina Faso

Decision

JCB decided to reduce the STAC membership from 21 to 15 members with the possibility for the Chair to co‐opt experts on an ad hoc basis when and if needed and within the budget allocated to STAC.


.

14. Review of TDR key achievements since JCB(34) and outlook 2012‐2013

Key messages

JCB commended the Director TDR for his presentation which was considered useful for the donors and for fundraising.

15. Summary of decisions and recommendations

Key messages

The Rapporteur presented the decisions and key recommendations of JCB(35) which were noted with thanks by the Board.

16. Closing session

Concluding remarks

Dr Marie‐Paule Kieny, ADG/IER, expressed her appreciation and thanks for the continued commitment demonstrated at this meeting by the JCB participants towards the Special Programme.

The Chair of JCB thanked the participants and TDR staff who all contributed to the success of this annual session of the Board.

Recommendation

JCB advised TDR to give more visibility to donors of undesignated (core) funds when reporting on its achievements.

Decision

JCB(36) will take place in Geneva from 17‐19 June 2013.

Recommendation

Consideration should be given to reducing the duration of the JCB meeting to 2 full days.

TDR/JCB(35)/12.3 .

ANNEX 1

AGENDA OF THE THIRTY-FIFTH SESSION OF THE JOINT COORDINATING BOARD (JCB)

MONDAY, 18 JUNE

Time Agenda item Action Reference Documents

09:00-09:30 Opening Remarks

Dr Sue Kinn, Chair of JCB

Dr Hiroki Nakatani, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases

Dr John Reeder, Director TDR

09:30-10:00 1. Statutory business

1.1 Election of the Vice-Chair and Rapporteur

TDR will propose an amendment to the MOU to extend the term of office of the Chair and Vice-Chair, JCB.

Decision on proposed extension of term of office of Chair and Vice-Chair JCB

Election of Vice Chair and Rapporteur from among the JCB members

1.2 Approval of the Report of JCB(34)

It is proposed that future JCB reports will only summarize recommendations and decisions and will be circulated for electronic approval within two weeks of the meeting.

Approval of JCB(34) report

Decision on proposed new format of JCB reports and approval procedure

Report JCB(34) TDR/JCB(34)/11.3

1.3 Adoption of the Agenda Adoption of agenda

Draft Agenda TDR/JCB(35)/12.1

Draft Annotated Agenda TDR/JCB(35)12.1a

10:00-10:10 2. Report by the Chair of the Joint Coordinating Board

Dr Sue Kinn, Chair since JCB(34), will report on her activities as Chair since the Thirty-fourth JCB Session.

Information

10:10-10:20 3. Report of the Standing Committee

Dr Armin Fidler, Representative of the World Bank and current Chair of the Standing Committee, will report on the Standing Committee’s activities since JCB(34).

Information

10:20-10:50 COFFEE BREAK

10:50-11:30 4. Report by the Chair, TDR Scientific and Technical Advisory Committee (STAC)

Professor Mario Henry Rodriguez-Lopez, Chair of STAC, will provide a summary of the activities of STAC and present the STAC report.

Information and approval of STAC report

Report Chair STAC TDR/STAC(34)/12.3


.

MONDAY, 18 JUNE (continued)


11:30-13:00 5. TDR programme review

11:30-11:40 5.1 Follow-up to the JCB(34) decisions and recommendations

Dr John Reeder, Director TDR, will provide an overview on the follow-up action taken on decisions and recommendations of JCB(34).

Information Report JCB(34) (pages 3-7) TDR/JCB(34)/11.3

11:40-11:55 5.2 Interim External Review

Dr Sue Kinn, Chair JCB, will present the key findings of the External Review and the follow-up action taken by TDR.

Information Interim External Review and Evaluation (December 2011)

Interim External Review – Briefing notes for the JCB TDR/JCB(35)/12.14

11:55-13:00 5.3 Operational and financial performance

Dr Beatrice Halpaap, Programme and Portfolio Manager, will present an overview of TDR’s financial performance in the biennium 2010-2011 and outline the current financial situation of TDR.

Dr Fabio Zicker, TDR Coordinator, will provide an overview on TDR’s operational performance.

Information and endorsement of TDR Results Report 2011

TDR Financial Report 2010-2011 and Financial Situation as at 1 May 2012 TDR/JCB(35)/12.4/rev1

Opinion of the External Auditor of WHO and Audited TDR financial statements for the 2010-2011 biennium TDR/JCB(35)/12.5

TDR Results Report 2011 TDR/JCB(35)/12.6

TDR Biennial Report 2010-2011 ISBN 978 92 4 150356 3

13:00-14:30 LUNCH BREAK

14:30-18:00 6. Programme Budget 2012-2013 and future strategic directions

14:30-15:30 6.1 Future strategic direction and reorganization

Dr John Reeder will present the proposed future strategic direction of TDR and its planned further reorganization.

Endorsement of proposed strategic directions and reorganization

Draft TDR Strategic Plan 2012-2017 TDR/STRA/12.2


16:00-17:00 6.1 Future strategic direction and reorganization (continued)

17:00-18:00 6.2 Workplan and Programme Budget for the biennium 2012-2013 and outlook for the biennium 2014-2015

Dr Beatrice Halpaap will present the key elements of the Workplan and Programme Budget for the biennium 2012-2013 and provide a financial outlook for the biennium 2014-2015.

Endorsement of Workplan and Programme Budget for the Biennium 2012-2013

TDR Programme Budget for the Biennium 2012-2013 TDR/JCB(35)/12.8

18:00-20:00 JCB RECEPTION (WHO CAFETERIA, MAIN BUILDING)

TDR/JCB(35)/12.3 .

TUESDAY, 19 JUNE


09:00-09:30 7. Summary of recommendations and decisions of day 1

The Rapporteur will present a summary of recommendations and decisions.

Information and discussion

09:30-11:00 8. Review of TDR governance

A representative of the JCB Working Group on Governance, will present the proposals of the JCB Working Group on TDR governance.

Decisions on strengthening TDR governance

Strengthening TDR Governance: Options for decision-making by JCB(35) TDR/JCB(35)/12.9

Memorandum of Understanding TDR/CP/78.5/Rev.2008


11:30-12:30 9. Resource Mobilization and Communications Strategy

Mr Meinrad Studer, Manager, External Relations and Governing Bodies, will point out priorities and challenges for resource mobilization.

Ms Jamie Guth, Communications Manager, will outline TDR’s communications strategy and priorities.

Advice and recommendations on TDR’s resource mobilization and communications priorities

Update on Resource Mobilization and Revenue Forecast TDR/JCB(35)/12.10

TDR Communications and Advocacy Plan for 2012 and beyond TDR/JCB(35)/12.11

12:30-14:00 LUNCH BREAK

14:00-15:00 10. Technical Presentation

TDR-led implementation research for better control of pneumonia and malaria at community level in Burkina Faso

Dr Sodiomon Sirima, Director, National Malaria Research and Training Center, Burkina Faso, will present the ongoing TDR community-based implementation research in Burkina Faso. His presentation will be preceded by the screening of a short film on the project.

Information


15:30-16:30 11. Global Report for Infectious Diseases of Poverty

Professor David Molyneux, Liverpool School of Tropical Medicine and co-author of the Global Report for Research on Infectious Diseases of Poverty, will offer some reflections on key messages and follow-up actions.

Discussion and recommendations on the dissemination of and follow-up to the Global Report

Global Report for Research on Infectious Diseases of Poverty ISBN 978 92 4 156 448 9

16:30-17:00 Summary of recommendations and decisions of day 2

The Rapporteur will present a summary of the recommendations and decisions.

Information and discussion


.

WEDNESDAY, 20 JUNE


08:30-09:00 Closed meeting of TDR resource contributors for the selection of four JCB members under paragraph 2.2.1 of the TDR Memorandum of Understanding

Selection of four JCB members under paragraph 2.2.1 of the MOU

09:00-09:45 12. Selection of JCB members

Note on the membership of the JCB TDR/JCB(35)/12.12

History of JCB Membership, 1978-2012

12.1 Results of the election of four members under Paragraph 2.2.1 of the TDR Memorandum of Understanding

Information

12.2 Selection of two members of the JCB according to Paragraph 2.2.3 of the TDR Memorandum of Understanding

Selection of two JCB members under paragraph 2.2.3 of the MOU

09:45:10:15 13. Membership of the Scientific and Technical Advisory Committee (STAC)

Decision on size of membership and call for applications to fill future vacancies

STAC Membership including Terms of Reference TDR/JCB(35)/12.13


10:45-11:45 14. Review of TDR key achievements since JCB(34) and outlook 2012-2013

Dr John Reeder will highlight TDR’s key achievements in the last year and provide an outlook on expected results in 2012-2013.

Information

11:45-12:15 15. Summary of decisions and recommendations

The Rapporteur will present a summary of the recommendations and decisions of JCB(35).

Review of decisions and recommendations

12:15-12:30 16. Closing session

Date and place of JCB(36)

It is proposed that JCB(36) will be held in Geneva from 17-19 June 2013.

Any other business

Concluding remarks

Dr Sue Kinn and Dr Marie-Paule Kieny

Decision on date and place of JCB(36)

TDR/JCB(35)/12.3 .

ANNEX 2

FINAL LIST OF PARTICIPANTS

MEMBERS BELGIUM

Dr Ignace RONSE, Expert en santé publique des Programmes Multilatéraux et Européens, Ministère de la Coopération au Développement, Bruxelles BRAZIL

Not able to attend. CHINA

Dr XIAO Ning, Deputy Director, National Institute of Parasitic Diseases (IPD), Shanghai CONGO

Dr Paul Macaire OSSOU-NGUIET, Chef de Service Recherche et Equipement au CHU de Brazzaville, Service de neurologie, CHU de Brazzaville, Brazzaville CÔTED'IVOIRE

Not able to attend. CUBA

Dr Jorge PÉREZ, Director General, Institute of Tropical Medicine "Pedro Kourí" (IPK), La Habana DJIBOUTI

Dr Houssein Youssouf DARAR, Head of Department, Infectious Diseases at Teacher Hospital General Peltier, Focal point of Infectious Diseases Research (MOH), Djibouti DRUGSFORNEGLECTEDDISEASESINITIATIVE

Dr Bernard PÉCOUL, Executive Director, Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland ECUADOR

Dr Carlos Gregorio MONTALVO, National Secretary, Public Health Serveillance (Advisor), Ministerio de Salud Pública, Quito EGYPT

Dr Ayat Atef Mohamed HAGGAG, Undersecretary for Endemic Diseases, Cairo


.

GERMANYANDLUXEMBOURGCONSTITUENCY

Dr Detlef BOECKING, Scientific Officer, PT-DLR, Project Management on behalf of the German Federal Ministry of Education and Research (BMBF), Bonn, Germany Professor Rolf KORTE, Senior Health Policy Advisor, Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, Eschborn, Germany Mme Anne WEBER, Agent de la Cooperation, Mission permanente du Grand-Duché de Luxembourg auprès de l'Office des Nations Unies à Genève, Switzerland INDIAANDTHAILANDCONSTITUENCY

Dr Wanna HANSHAOWORAKUL, Director, Bureau of Knowledge Management, Department of Disease Control, Ministry of Public Health, Royal Thai Government, Nonthaburi, Thailand Dr Kanikaram SATYANARAYANA, Scientist G, Department of Health Research, Indian Council of Medical Research, New Delhi, India INDONESIA

Dr TRIHONO, Director General National Institute of Health Research & Development, Ministry of Health, Jakarta Pusat IRAN(ISLAMICREPUBLICOF)

Dr Payman HEMMATI, Expert in Influenza and IHR, Ministry of Health and Medical Education, Tehran IRAQ

Dr Ataallah M. Turky TURKY, Manager, Viral Hepatitis Department, Public Health Directorate, Baghdad JAPAN

Dr Haruka SAKAMOTO, Section Chief, Department of International Cooperation, Ministry of Health, Labour and Welfare, Tokyo LAOPEOPLE'SDEMOCRATICREPUBLIC

Dr Kongsap AKKHAVONG, Acting Director General, National Institute of Public Health, Ministry of Health, Vientiane Capital MALAYSIA

Dr Shahnaz MURAD, Director, Institute for Medical Research, Ministry of Health, Kuala Lumpur NEPAL

Dr Saroj Prasad RAJENDRA, Director, Management Division, Ministry of Health and Population, Government of Nepal, Kathmandu NIGERIAANDGHANACONSTITUENCY

Professor Karniyus Shingu GAMANIEL, Director General, National Institute for Pharmaceutical Research and Development (NIPRD), Garki - Abuja, Nigeria

TDR/JCB(35)/12.3 .

NORWAYANDSWITZERLANDCONSTITUENCY

Mr Marc DE SANTIS, Programme Manager - Multilateral Affairs, East and Southern Africa, Federal Department of Foreign Affairs, Swiss Agency for Development and Cooperation SDC, Bern, Switzerland Mrs Helga FOGSTAD, Head of Health, Department of Global Health, Education and Research, Norwegian Agency for Development Cooperation (NORAD), Oslo, Norway PERU

Dr Cesar Augusto CABEZAS SÁNCHEZ, Medical Researcher, National Institute of Health, Lima PORTUGAL

Not able to attend. REPUBLICOFKOREA

Dr KIM Jung-Yeon, Staff Scientist, Division of Malaria and Parasitic Diseases, Korea National Institute of Health, Korea Centers for Disease Control & Prevention, Chungbuk Dr LEE Won-Ja, Director, Division of Malaria & Parasitic Diseases, Korea National Institute of Health, Korea Centers for Disease Control & Prevention, Chungbuk SPAINANDPANAMACONSTITUENCY

Dr Carlos SEGOVIA, Deputy Director for International Research Programmes and Institutional Relations, Instituto de Salud Carlos III, Madrid, Spain SWEDENANDNETHERLANDSCONSTITUENCY

Professor Maria Teresa BEJARANO, Senior Policy Specialist, Research, Swedish International Development Cooperation Agency - Sida, Stockholm, Sweden Ms Marja ESVELD, Senior Health Advisor, Social Development Department (DSO), The Hague, Netherlands Ms Henriëtte VAN GULIK, First Secretary, Permanent Mission of the Kingdom of the Netherlands to the United Nations Office and Other International Organizations at Geneva TAJIKISTAN

Dr Sayfuddin KARIMOV, Director, National Center for Control of Tropical Diseases, Dushanbe Dr Rano RAHIMOVA, Chief Specialist, Department of Reform and International Relations, Ministry of Health, Dushanbe UNITEDARABEMIRATES

Not able to attend.


.

UNITEDKINGDOMOFGREATBRITAINANDNORTHERNIRELANDANDUNITEDSTATESOFAMERICACONSTITUENCY

Dr Sue KINN, Team Leader Human Development, Research and Evidence Division, Department for International Development (DFID), Glasgow, Great Britain Mr Malcolm McNEIL, Senior Health Adviser, Human Development Team, Research and Evidence Division, Department for International Development (DFID), London, Great Britain Mr Martin SMITH, Deputy Programme Manager, DFID Research, Great Britain ZAMBIA

Mr Evans MALIKANA, Chief Policy Analyst, Ministry of Health, Lusaka Mr Samson LUNGO, First Secretary, Permanent Mission to the United Nations, Geneva Dr Modest MULENGA, Director, Tropical Diseases Research Centre, Ndola UNITEDNATIONSCHILDREN'SFUND(UNICEF)

Ms Susie VILLENEUVE, Health Specialist, United Nations Children's Fund (UNICEF), Geneva, Switzerland UNITEDNATIONSDEVELOPMENTPROGRAMME(UNDP)

Mr Jeffrey O'MALLEY, Director, HIV/AIDS Group, Bureau for Development Policy, New York, NY, USA WORLDBANK

Dr Armin FIDLER, Lead Health Policy Adviser, Human Development, World Bank, Washington, DC, USA Mrs Oksana PIDUFALA, Policy Officer, World Bank, Geneva, Switzerland WORLDHEALTHORGANIZATION HEADQUARTERS,GENEVA,SWITZERLAND

Dr Bernadette ABELA-RIDDER, Scientist, Department of Food Safety and Zoonoses (FOS) Foodborne Disease and Epidemiology Dr Nicholas BANATVALA, Special Adviser to the Assistant Director-General, Noncommunicable Diseases and Mental Health Ms Gian Luca BURCI, Legal Counsel Mr Nick JEFFREYS, Comptroller and Director, Department of Finance (FNM) Dr Marie-Paul KIENY, Assistant Director-General, Innvovation, Information, Evidence and Research Dr Christian LIENHARDT, Senior Research Adviser, STB Policy, Strategy and Innovations

TDR/JCB(35)/12.3 .

Dr Simone MAGNINO, Scientist, Department of Food Safety and Zoonoses (FOS), Foodborne and Zoonotic Diseases Ms Anne MAZUR, Principal Legal Officer Dr Hiroki NAKATANI, Assistant Director-General, HIV/AIDS, TB, Malaria and Neglected Tropical Diseases Dr Lorenzo SAVIOLI, Director, Neglected Tropical Diseases SPECIALPROGRAMME(TDR)

Ms Jamie GUTH, Communications Manager Dr Beatrice HALPAAP, Programme and Portfolio Manager

Dr John REEDER, Director

Meinrad STUDER, Manager, External Relations and Governing Bodies Fabio ZICKER, Coordinator, Research / Acting Coordinator, Stewardship and Empowerment

REGIONALOFFICES

RegionalOfficefortheWesternPacific

Dr John EHRENBERG, Director, Combating Communicable Diseases, Manila

SCIENTIFIC AND TECHNICAL ADVISORY COMMITTEE (STAC)1Professor Mario Henry RODRIGUEZ-LOPEZ, Researcher at the Center for Research for Infectious Diseases, National Institute of Public Health, Ministry of Health, Cuernavaca, Morelos, Mexico

TECHNICAL PRESENTERS

Dr Sodiomon Bienvenu SIRIMA, Scientific Team Leader, Ouagadougou, Burkina Faso Professor David MOLYNEUX, Emeritus Professor and Senior Professorial Fellow, Liverpool School of Tropical Medicine, Liverpool, United Kingdom

1 Dr M.H. Rodriguez-Lopez was also appointed to represent the Government of Mexico.


.

OBSERVERS COHRED‐COUNCILONHEALTHRESEARCHFORDEVELOPMENT(INCORPORATINGTHEGLOBALFORUMFORHEALTHRESEARCH)

Dr Francisco SONGANE, Chair of the Steering Committee, Forum 2012, COHRED, Geneva, Switzerland FRANCE

Mme Geneviève CHEDEVILLE-MURRAY, Conseiller, Questions relatives à la santé, Mission permanente de la France auprès des Nations Unies, Chambésy / Genève, Switzerland INTERNATIONALDEVELOPMENTRESEARCHCENTRE(IDRC)

Dr Dominique CHARRON, Program Leader, ECOHEALTH - Ecosystem Approaches to Human Health, International Development Research Centre (IDRC), Ottawa (Ontario), Canada MEXICO

Professor Mario Henry RODRIGUEZ-LOPEZ, Director, National Institute of Public Health, Ministry of Health, Cuernavaca, Morelos MYANMAR

Dr Htun Naing Oo, Director General, Department of Medical Research (Central Myanmar), Ministry of Health, Nay Pyi Taw SAUDIARABIA

Mr Saud Faleh AL-NOFAIE, First Secretary, Permanent Mission of Saudi Arabia to the United Nations in Geneva, 1292 Chambésy-Genève, Switzerland Ms Sarah AL SHOURA, Permanent Mission of Saudi Arabia to the UN in Geneva SIGHTSAVERS

Dr Elizabeth ELHASSAN, Regional Director, Sightsavers West Africa Regional Office, Dakar, Sénegal Dr Elena SCHMIDT, Head of Research, Sightsavers, Haywards Heath, United Kingdom SRILANKA

Dr Sunil DE ALWIS, Deputy Director General of Health Services, Education, Training and Research, Ministry of Health, Colombo WELLCOMETRUSTDr Dermot MAHER, International Portfolio Manager, Wellcome Trust, London, United Kingdom

TDR/JCB(3.

MEM

35)/12.3

MBERSHIIP OF TH

A

HE TDR JAS OF 1

ANNEX 3

JOINT C1 JANUA

3

OORDINARY 2013

NATING BBOARD (JCB)


.

ANNEX 4

MEMBERSHIP OF THE TDR STAC AS OF 1 JANUARY 2013

Term of Office

(until 31 December)

Professor Maged AL-SHERBINY, President, NAM S&T Centre and President, Academy of Scientific Research and Technology (ASRT), Academy of Scientific Research and Technology (ASRT), Cairo, Egypt

2010-2013

Professor Myriam AREVALO-HERRERA, Professor, School of Health, Department of Clinical Laboratory, Universidad del Valle, Cali, Colombia

2010-2013

Dr Vicente Y. BELIZARIO, Jr., Vice-Chancellor for Research and Executive Director, National Institutes of Health, University of the Philippines, Manila, Philippines

2008-2013

Dr Yves CHAMPEY, Chair, Strategic Committee for the Pole Development and its Ecosystem (DevEco), Paris, France

2008-2013

Dr Carol A. DAHL, Executive Director, The Lemelson Foundation, Portland, USA 2008-2013

Professor Asma ELSONY, Director, The Epidemiological Laboratory, Khartoum, Sudan

2010-2013

Professor Bruno GRYSEELS, Director, Institute of Tropical Medicine, Antwerpen, Belgium

2012-2013

Dr Ikram GUIZANI, Head of Laboratory, Institut Pasteur de Tunis, Ministère de la Santé Publique, Tunis-Belvedere, Tunisia

2012-2013

Dr Vishwa KATOCH, Secretary to the Government of India, Department of Health Research & Director General, Indian Council of Medical Research, Ministry of Health & Family Welfare, New Delhi, India

2010-2013

Dr Poloko KEBAABETSWE, Director, Health Service Research Unit, University of Botswana, Gaborone, Botswana

2012-2013

Professor Christos (Kitsos) LOUIS, Chairman, Department of Biology, University of Crete, Crete, Greece

2008-2013

Dr Florencia LUNA, Director, Bioethics Program of FLACSO, Latin American University of Social Sciences, Buenos Aires, Argentina

2012-2013

Professor Lenore MANDERSON, Professor of Medical Anthropology and ARC Federation Fellow and Director, Social Sciences and Health Research Unit, Caulfield Campus, Monash University, Caulfield East, Australia

2012-2013

Professor Anne J. MILLS, Vice Director for Academic Affairs, London School of Hygiene and Tropical Medicine, London, United Kingdom

2008-2013

Professor Mario-Henry RODRIGUEZ-LOPEZ, Researcher at the Center for Research for Infectious Diseases, National Institute of Public Health, Morelos, Mexico

2009-2014

Dr Ananda Rajitha (Raj) WICKREMASINGHE, Dean of the Faculty of Medicine & Professor of Public Health, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka

2012-2013